Basophilic inclusions (BIs) are pathological features of a subset of frontotemporal lobar degeneration disorders, including sporadic amyotrophic lateral sclerosis (ALS) and familial ALS (FALS). Mutations in the fused in sarcoma/translocated in liposarcoma (FUS/TLS) gene have recently been identified as a cause of FALS. The FUS/TLSimmunoreactive inclusions are consistently found in cases of frontotemporal lobar degeneration with BIs; however, the association between ALS cases with BIs and FUS/TLS accumulation is not well understood. We used immunohistochemistry to analyze 3 autopsy cases of FALS with the FUS/TLS mutation and with BIs using anti-FUS/TLS antibodies. The disease durations were 1, 3, and 9 years. As the disease duration becomes longer, there were broader distributions of neuronal and glial FUS/TLS-immunoreactive inclusions. As early as 1 year after the onset, BIs, neuronal cytoplasmic inclusions and glial cytoplasmic inclusions were found in the substantia nigra in addition to the anterior horn of the spinal cord. Glial cytoplasmic inclusions are found earlier and in a wider distribution than neuronal cytoplasmic inclusions. The distribution of FUS/TLS-immunoreactive inclusions in FUS/TLSmutated FALS with BIs was broader than that of BIs alone, suggesting that the pathogenetic mechanism may have originated from the FUS/ TLS proteinopathy.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder characterized by the death of motor neurons (1) . Autosomal-dominant familial cases account for nearly 10% of ALS cases. Approximately 10% to 20% of familial ALS (FALS) cases are caused by mutations in the superoxide dismutase 1 (SOD1) gene (1, 2) . Mutations in the TARDBP gene, which codes for TAR DNAYbinding protein 43 (TDP-43), have also been reported in FALS cases (3) .
Recently, 2 groups reported that the autosomal dominant form of FALS is caused by mutations in the fused in sarcoma/ translocated in liposarcoma (FUS/TLS) gene (4, 5) , following several reports of both familial and sporadic cases from Europe (6Y9) and Japan (10, 11) . The FUS/TLS is a nucleoprotein that is involved in DNA and RNA metabolism (12) . It binds to mRNA/DNA or other heterogeneous nuclear ribonucleoproteins through its C-terminus, regulating the splicing and transport of pre-mRNA; binding of its N-terminus to polymerases leads to transcriptional activation. Using an in vitro model, the nuclear localization signal in the C-terminus of FUS/TLS was found to be necessary for nuclear import (13Y15).
Neuropathologic examination in FUS/TLS ALS cases has revealed severe lower motor neuron loss in the spinal cord and to a lesser degree in the brainstem as well as mild to moderate upper motor neuron loss in the motor cortex (10) . Immunohistochemical staining of FUS/TLS within neuronal and non-neuronal nuclei is observed in both controls and patients with ALS, whereas additional promnent cytoplasmic FUS/TLS staining or elongated inclusions in spinal cord motor neurons and dystrophic neurites are found only in ALS patients. Subsequent studies have found FUS/TLSimmunoreactive (ir) neuronal cytoplasmic inclusions (NCIs) and glial cytoplasmic inclusions (GCIs) in tau-negative and TDP-43Ynegative frontotemporal lobar degeneration (FTLD), including atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion (BI) body disease (16) .
Munoz et al (16) reported the occurrence of FUS/TLS-ir NCIs, dystrophic neuritis, and GCIs in 2 cases of SALS with BIs that were previously reported by Kusaka et al (17) . More recently, Tateishi et al (18) identified the R521C mutation in the FUS/TLS gene in FALS cases with BIs and found FUS/ TLS-ir BIs and GCIs in affected areas. These findings suggest the possibility that BIs and FUS/TLS-ir structures are both pathological hallmarks of a subset of FALS and SALS cases. We have also reported another Japanese FALS family with the R521C FUS/TLS mutation and BIs (11) .
Here, we report a large Japanese FALS family with R521C mutations in the FUS/TLS gene with early disease onset. We performed pathological examinations on 3 autopsy cases with disease durations of 1, 3, or 9 years.
MATERIALS AND METHODS

ALS Cases
The family history revealed FALS in 23 of 46 family members (Fig. 1) , suggesting a 100% penetrance rate (11) . The average disease onset was at 35.3 T 5.1 years (n = 12). The disease duration (from onset to respiratory failure) was 16.1 T 7.7 months. The disease course was rapidly progressive, and the average age of death was 37.2 T 4.2 years (n = 12). We did not find any cognitive impairment in the FALS patients with the FUS/TLS mutation in generations IV to VI of the family (Fig. 1) .
Patient 1 was a man with an autosomal-dominant hereditary burden, as described in a previous report (11) . At age 30 years, he developed muscle weakness in the distal part of his right upper extremity, followed by dysarthria, dysphagia, muscle weakness, and atrophy in all 4 extremities. Sensory, cerebellar, and higher cortical functions were not affected. At age 31 years, he required ventilatory support. He died of bronchopneumonia at age 40 years, that is, 9 years after disease onset.
Patient 2 was a woman described in a previous report, who suffered from FALS with posterior column degeneration and BIs (10, 19) . At age 42 years, she developed muscle weakness in the proximal part of her upper extremities, followed by dysarthria, dysphagia, muscle weakness, and atrophy in her lower extremities. At age 44 years, she required ventilatory support. She died of bronchopneumonia at age 45 years, that is, her total disease duration was 3 years.
Patient 3 was a 48-year-old woman who started to notice muscle weakness in her right hand and muscle cramps in both legs. Five months later, she developed muscle weakness in all 4 limbs and subsequently noticed shortness of breath. Approximately 1 year after the onset of symptoms, she began to have difficulty in excreting sputum and developed dyspnea. She died of respiratory failure almost 1 year after the onset of her symptoms.
Genetic Examination
After written informed consent was obtained, DNA extraction and genotyping were performed using standard protocols, as previously described (11, 20) . We sequenced all the exons from patient 1. The study was approved by the Ethics Committee (2009Y384).
Neuropathologic Examination
Brain tissue samples were fixed postmortem with 10% formalin and embedded in paraffin, as previously described (5) . Six-micrometer-thick tissue sections were prepared from the frontal, temporal, parietal, occipital, insular, and cingulate cortices, hippocampus, amygdala, basal ganglia, midbrain, pons, medulla oblongata, cerebellum, and the cervical, thoracic, lumbar, and sacral spinal cord. Deparaffinized sections were incubated for 30 minutes in 0.3% H 2 O 2 to quench endogenous peroxidase activity and then washed with PBS. Sections were stained using the hematoxylin and eosin (H&E) and Klüver-Barrera (KB) methods. The severity of neuronal loss and tract degeneration was evaluated as none (j), mild (+), or severe (++). The presence of BIs was scored as absent (j), present (p), or prominently present (pp) ( Table) .
Rabbit polyclonal antiYTDP-43 (1:500; Protein Tech, Chicago, IL), rabbit polyclonal anti-ubiquitin (1:1000; Abcam, Cambridge, UK), and rabbit polyclonal anti-FUS/TLS (1:200, A300-302A; Bethyl, Montgomery, TX) antibodies were used. The reaction products were visualized with 3,3 ¶-diaminobenzidine tetrahydrochloride, and hematoxylin was used to counterstain cell nuclei. The FUS/TLS-ir structures were assessed and 
scored as none (j), rare (+), occasional (++), common (+++), or numerous (++++), as previously described (10) (Table) .
RESULTS
Mutation Analysis
We detected a missense mutation (c.1561CYT) in the FUS/TLS gene that substituted cysteine for arginine at residue 521 (R521C) in patient 1 (11) . A sequence analysis of the FUS/TLS gene in patients 2 and 3 could not be performed because only formalin-fixed and paraffin-embedded tissues were available. Identification of the R521C FUS/TLS mutation in patient 1 suggests that patients 2 and 3 likely carried the same FUS/TLS mutation.
Neuropathologic Findings
The distribution and severity of neuronal degeneration, BIs, and FUS/TLS-ir structures across CNS regions are summarized in the Table. Examination of patient 1 revealed neuronal loss in the upper and lower motor neuron systems and Clarke column and degeneration of the pyramidal tracts, the middle root zone of the posterior column, and the posterior spinocerebellar tract. Atrophy of the brainstem tegmentum was remarkable. There was marked neuronal loss in the anterior horn of the spinal cord. Neuronal loss was also noted in the substantia nigra, globus pallidus, periaqueductal gray matter, oculomotor nucleus, reticular formation of the brainstem, red nucleus, cerebral peduncle, motor nucleus of the trigeminal nerve, locus coeruleus, central tegmental tract, pontine nucleus, hypoglossal nucleus, and the gracile nucleus. Betz cells were sparse in the primary motor cortex versus the primary cortices of normal controls. Along the entire spinal cord, the anterior and lateral funiculi, including the spinothalamic and spinocerebellar tracts, were extensively degenerated. The BIs were observed in H&E-and KB-stained sections and were detected in Betz cells, the globus pallidus, subthalamic nucleus, substantia nigra, red nucleus, periaqueductal gray matter, locus coeruleus, oculomotor nucleus, pontine nucleus, lateral cuneate nucleus, gracile nucleus, reticular formation of the medulla oblongata, cerebellar dentate nucleus, and anterior horn of the lumbar cord ( Fig. 2A, B) (11) . Most BIs were homogeneous and round without a halo or core, as previously reported (21) . The color of the BIs in the H&E-stained sections was closer to pink than blue, with occasional thin basophilic rims, which is consistent with some previous descriptions (22) . The basophilic bodies were ubiquitin ir (Fig. 2F ), but not TDP-43 ir (Fig. 2E) (11) . Numerous FUS/TLS-ir inclusions were found in neurons and glial cells (Fig. 2C, D) .
Examination of patient 2 has been previously described (10, 19) and is summarized in the Table. The distribution of degeneration was not as broad as in patient 1. Degeneration was observed in the primary motor cortex, subthalamic nucleus, periaqueductal gray matter, red nucleus, medial longitudinal fasciculus, cerebral peduncle, locus coeruleus, superior cerebellar peduncle, pontine nucleus, dorsal vagal nucleus, nucleus tractus solitarius, inferior olivary nucleus, medial lemniscus, dentate nucleus, cerebellar white matter, and Clarke nucleus. We found BIs in the primary motor cortex, subthalamic nucleus, substantia nigra, periaqueductal gray matter, locus coeruleus, pontine nucleus, gracile nucleus, cuneate nucleus, reticular formation, dentate nucleus, and the anterior horn (Table) . In addition, there were NCIs and GCIs in the frontal white matter, putamen, globus pallidus, thalamus, oculomotor nucleus, reticular formation, and the posterior horn.
In patient 3, KB staining showed severe loss of anterior horn neurons compared with a control (Fig. 3A, B) . The BIs were observed in both H&E (Fig. 3C )-and KB-stained sections (Fig. 3D) . The FUS/TLS-ir cytoplasmic inclusions were present in surviving motor neurons (Fig. 3E ). Glial cells with FUS/TLS-ir cytoplasmic inclusions appeared to be oligodendroglia (Fig. 3F) . Degeneration was only found in the anterior horn, substantia nigra, corticospinal tract, and the middle root zone. The BIs were only present in the substantia nigra and anterior horn of the spinal cord (Table) . The NCIs were found in the substantia nigra, locus coeruleus, and the anterior horn of the spinal cord. The GCIs were also found in the substantia nigra, anterior horn, corticospinal tract, and cuneate fasciculus of the spinal cord (Table) .
The FUS/TLS-ir inclusions were distributed more widely with longer disease durations. Figure 4 illustrates inclusions in the basal ganglia (Fig. 4A, E) , midbrain (Fig. 4B, F) , upper pons (Fig. 4 C, G) , and cervical spinal cord (Fig. 4D, H ) in patient 3 (Fig. 4AYD) and patient 1 (Fig. 4EYH) . The FUS/ TLS-ir inclusions were counted and are represented semiquantitatively in the anterior horn and substantia nigra, respectively (Fig. 5A, B) ; however, we were not able to evaluate them thoroughly. With respect to NCIs, the anterior horn cells were severely degenerated, and many NCIs were found in the anterior horn cells even in patients 2 and 3. Most of the neurons that disappeared in patient 1 resulted in decreased numbers of NCIs; thus, the decrease in NCIs in the anterior horn resulted from the loss of anterior horn cells. In contrast, we detected an increase in the number of NCIs in the substantia nigra in the case with long (9 years) versus short (1 year) duration. There were numerous GCIs in the anterior horn in patient 2 and fewer GCIs in patient 1. In the substantia nigra, the number of GCIs was also greater in the case of long versus short duration. The apparent early appearance of FUS/TLS-ir inclusions and severe degeneration in the terminal stage in the anterior horn indicated that the motor neuron system was the most severely affected region in FUS/TLS-mutated FALS, although multiple systems were involved in the advanced disease.
DISCUSSION
Recent work suggests a new biochemical category of neurodegenerative diseases in terms of the aberrant accumulation of FUS/TLS (FUS/TLS proteinopathy). The FUS/TLS mutations have been found in 3% to 5% of patients with FALS (4, 5, 8, 9, 23) and in some SALS cases (7, 24) . The R521C mutation is one of the most common. As reported previously in cases with this type of mutation, weakness of the neck and/or proximal upper limbs is frequently observed, and bulbar dysfunction, dystonia, or frontotemporal dementia are rarely observed; there is no sensory disturbance, ataxia, or parkinsonism. The clinical features of the present cases are largely consistent with those previously reported. To date, 6 papers have described the neuropathology of patients with the R521C mutation (4, 5, 10, 18, 25, 26) , but this study is the first to describe temporally serial pathological examinations in affected family members that presumably had the same mutation. Recently, Neumann et al (27) reported that the FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS/TLS pathology from ALS with the FUS/TLS mutation. In this series, however, none of the 3 cases had cognitive impairment.
Although the marked loss of NCIs in patient 1 may be caused by the long disease duration and the use of artificial ventilation and not because of the FUS/TLS mutation itself, this is the first report of serial autopsied FALS cases with BIs in the same family showing a widespread occurrence of FUS/TLS-ir neuronal and glial inclusions. Patients in this family likely had the same mutation as patient 1 based on the autosomal-dominant trait pattern (Fig. 1) .
It is noteworthy that the distributions of FUS/TLS-ir structures and degeneration occurred largely in parallel in the cerebrospinal regions (Table) . Aberrant accumulation of FUS/ TLS plays an important role in degeneration. In patient 3, prominent neuronal degeneration was found in the anterior horn of the spinal cord and only extended to the substantia nigra. As we observed in the relatively earlier stages of ALS, there is multisystem degeneration despite the fact that clinical manifestations are restricted to the motor system. The middle root zone of the spinal cord had degenerated even in the early disease stage in patient 3. Although the middle root zone had degenerated in an SOD1-mutated ALS patient (28) , it was also the characteristic finding in FUS/TLS-mutated ALS patients. Before the identification of the FUS/TLS mutation as the cause for the disease, FALS with BIs was described in some reports (17, 19, 29, 30) . From our extensive survey, we found broader distributions of FUS/TLS-ir structures than those of BIs, suggesting that degeneration beyond the motor neuron system had occurred in our patients even in the early stages of the disease. On the other hand, in some respirator-assisted patients with sporadic ALS who survived long-term, the degeneration did not extend beyond the upper and lower motor neurons (28, 31) . In addition, in 2 patients with long-term sporadic ALS without respirator support (1 with a 9-year history and the other with an 11-year history), the pathological findings were similar to those of typical classical ALS (28) . This suggests that the multisystem degeneration of our autopsy cases does not seem to be simply attributable to the long-term survival assisted by ventilator support.
Pathogenetic mechanisms of FUS/TLS-mutated ALS have not been elucidated. Glial cells carrying a human SOD1 mutation have a direct non-cell autonomous effect on motor neuron survival (32, 33) . Whether the aberrant expression of FUS/TLS in glial cells also has a non-cell autonomous effect on motor neuron survival has not yet been examined. Here, we provide spatial and semiquantitative data on NCIs and GCIs in the spinal cord and substantia nigra (Figs. 4, 5) . With respect to NCIs, the anterior horn cells were severely degenerated and contained many NCIs even in patients 2 and 3. Most of the neurons that disappeared in patient 1 resulted in decreased numbers of NCIs, indicating that the decrease in NCIs was caused by the loss of anterior horn cells. In contrast, we detected increasing numbers of NCIs in the substantia nigra in the case of 9-year duration. We found many GCIs in the anterior horn in patient 2 and fewer in patient 1. In patient 2, we observed the pathology of ongoing neuronal degeneration, and GCIs were more prominent than NCIs in both the anterior horn and the substantia nigra. Thus, the GCIs appeared to be prominent in a transition period, that is, the middle disease duration of patient 2. Similar to pathogenesis of SOD1-mutated FALS, the non-cell autonomous effects of glial cells may influence the progression of FUS/TLS proteinopathy. In contrast, it has previously been reported that alsin-depleted ALS spinal motor neurons can be rescued from defective survival and axon growth through coculture with astrocytes in vitro (34) . It is possible that glial cells have a protective role by promoting the clearance of mutated FUS/TLS proteins from FUS/TLS-ir inclusions in neurons. The TDP-43 is detected in the spinal fluid of ALS patients (35) , which may indicate that FUS/TLS (which contains similar functional domains as TDP-43) may be excreted from neuronal cells and might be processed by glial cells. The role of glial cells carrying FUS/TLS mutation remains unclear.
There are various types of FUS/TLS-ir neurons. We observed several types of FUS/TLS-ir structures in patient 1 (Fig. 6AYD) . In patient 3, the frequency of NCI (Fig. 6D) was not very high, and most neuronal cells showed a nuclear FUS/ TLS staining pattern. Because the nuclear localization signal in the C-terminus of FUS/TLS was found to be necessary for nuclear import (13, 14, 15) , we propose that there is progression of the cytopathology of FUS/TLS proteinopathy such that 1) morphologically normal neurons have FUS/TLS-ir in the nucleus (Fig. 6 A) ; 2) there is the early occurrence of FUS/ TLS redistribution, including low expression in the nucleus and high expression in the cytoplasm (Fig. 6B) ; 3) this is followed by loss of staining in the nucleus with predominantly cytoplasmic staining (Fig. 6C) ; and 4) cytoplasmic FUS/TLS aggregates are found in atrophic neurons (Fig. 6D) . These observations may parallel the production of NCIs in FUS/TLSmutant transgenic cell models (14) .
There are many similarities between FUS/TLS and TDP-43. They are both DNA/RNA-binding proteins involved in transcriptional regulation, mRNA splicing, transport, and translation (36) . Mutations in both genes cause ALS (16) , and both gene products accumulate in neurons and glial cells. In our patient with the R521C FUS/TLS mutation, TDP-43 had a normal distribution. Regardless of their functional similarities, FUS/TLS and TDP-43 may contribute to the development of ALS by distinct molecular pathways. The messenger RNA or microRNA of these autopsy cases should be examined.
Recently, Huang et al (37) reported that FUS/TLS transgenic rats develop ALS and FTLD phenotypes. Mutant FUS/ TLS transgenic rats developed progressive paralysis secondary to the degeneration of motor axons and displayed a substantial loss of neurons in the cortex and hippocampus. Even transgenic rats that overexpressed the wild-type human FUS/TLS showed a deficit in spatial learning and memory and a significant loss of cortical and hippocampal neurons at advanced ages. A disease model using a knock-in system or a cellspecific mutant would be necessary to support our hypothesis on the mechanisms of the progression scenario that we hypothesize.
In conclusion, we have demonstrated a widespread occurrence of FUS/TLS-ir neuronal and glial structures in R521C-FUS/TLSYmutated FALS with BIs. Further studies using animal models are needed to examine the pathogenetic mechanisms of FALS-FUS/TLS.
